Myriad Genetics (NASDAQ:MYGN) Releases FY 2024 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,United States ,America ,Piper Sandler ,America Corp ,Goldman Sachs Group ,Wellington Management Group ,Vanguard Group Inc ,Wells Fargo Company ,Wolfe Research ,Genetics Company Profile ,Nuveen Asset Management ,Genetics Inc ,Myriad Genetics ,Get Free Report ,Management Group ,Street Corp ,Asset Management ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Myriad Genetics Daily ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Guidance ,Earnings ,Preannouncement ,